<DOC>
	<DOC>NCT02576717</DOC>
	<brief_summary>The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.</brief_summary>
	<brief_title>A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>The trial is an open label extension study. Eligible patients from the RPC01-201, RPC01-301, and RPC01-1001 trials diagnosed with relapsing Multiple Sclerosis (RMS) will be enrolled to receive study drug until the end of the trial or until the Sponsor discontinues the development program.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Eligibility Criteria: Completed one of the parent trials: RPC01201, RPC01301 or RPC011001 Does not have a condition that would require withdrawal from one of the parent trials (RPC01201, RPC01301, RPC011001) Has no conditions requiring treatment with a prohibited medication Ability to provide written informed consent and to be compliant with the schedule of protocol assessments Patients of reproduction potential (males and females) must practice an acceptable method of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>RMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>